ScheduleDay 1 : May 31 (Fri.), 2024

Room 1Room 2

Room 3

Poster Room501（5F）

502・503（5F）

411・412（4F）

409・410
（4F）

8:00

9:00

10:00

Educational Seminar 2024
forYoung Physicians
andMedical Staﬀs in Fukuoka

11:00

9:00 - 14:00

12:00

13:00

14:00

15:00

Annual General Meeting of Members(Board of Delegates)

15:00 - 16:00

16:00

Board of Directors Meeting

16:00 - 17:00

17:00

Evening Seminar 1

17:00 - 17:50

Updates in RRMM: evolving treatment strategies
for sequencing lImmune-based therapies
Chair: M. Abe
Speaker: N. Munshi【Bristol-Myers Squibb K.K.】
18:00

19:00

21ScheduleDay 2 : June 1 (Sat.), 2024

Room 1Room 2

Room 3

Poster Room501（5F）

502・503（5F）

411・412（4F）

409・410
（4F）

8:00

9:00

Opening Remarks
Symposium 1
9:00 - 10:30

10:00

Ｅ

Symposium 2
9:00 - 10:30

Therapies targeting the immune
microenvironment

Control and prevention of infectious diseases

Speakers:
M. Ichii, N. Munshi, G. Morgan, T. Harada

Speakers:
Y. Eriguchi, K. Suzuki, K. Serizawa, M. Saburi

Chairs:K. Tanimoto, T. Kamimura

Chairs:H. Tamura, M. Ichii

Poster Mounting

11:00

International Symposium
10:40 - 11:50

9:00 - 12:00

ＥOral Session1
10:40 - 11:50

Chairs:H. Kosugi, S. Iida

Basic and clinical research 1
Chairs:Y. Hattori, A. Sakai

Speakers:
S. Ozaki, S.-H. Jung, P. Moreau

12:00

Luncheon Seminar 1

12:00 - 12:50

Clinical Landscape and Future Horizons
in Multiple Myeloma Therapy:
advancing from MAIA and ALCYONE
Chair: I. Hanamura

Speaker: T. Kikuchi【Janssen Pharmaceutical K.K.】
13:00

Luncheon Seminar 2 12:00 - 12:50

Luncheon Seminar 3

Chair: N. Hosen
Speaker: T. Ishida

Chair: K. Nagafuji

Future Treatment Landscape ofmultiple myeloma【AbbVie GK】

12:00 - 12:50

Signiﬁcance of SARS-CoV-2 infection
in clinical setting in patients withhematologic malignancies
Speaker: A. Tomita【AstraZeneca K.K.】

General Membership Meeting
13:00- 13:30
Presidential Lecture

14:00

13:30- 14:00

Symposium 3
14:10 - 15:40

ＥSymposium 4
14:10 - 15:40

Geriatric assessments and rehabilitation

New treatment (CAR-T/bispeciﬁc antibody)
15:00

Chairs:H. Sasaki, S. Kamada

Chairs:T. Ishida, J. Kuroda

Speakers:
J.Y. Lee, K. Suzuki, S. Togashi, S. Kamada,
Y. Yamaguchi, S. Sakamoto

Speakers:
S. Iida, J.M. Byun、
M. Mohty, N. Munshi

16:00

Corporate Seminar 1

Corporate Seminar 2

15:50 - 16:40

Optimizing the outcome of
newly diagnosed multiple myeloma

17:00 - 17:50

15:50 - 16:40

Chair: Y. Furukawa

Speaker: M. Saburi【ONO PHARMACEUTICAL CO., LTD.】【Janssen Pharmaceutical K.K.】

Evening Seminar 2

Evening Seminar 3 17:00 - 17:50

Evening Seminar 4

17:00 - 17:50

How to optimize the beneﬁt ofimmune-based therapies in RRMM

Treatment strategy for Waldenströmʼsmacroglobulinemia in2024 and future prospects

Rationale of using Isatuximab in second-line treatment:
explaining Eﬃcacy and Safety from
Basic and Clinical Perspectives【Bristol-Myers Squibb K.K.】【ONO PHARMACEUTICAL CO., LTD.】【Sanoﬁ K.K.】

Chair: E. Sakaida
Speakers: A. Kitadate, N. Mimura

12:00 - 18:00

Role of carﬁlzomib for relapsed/refractory multiple myeloma inthe immunotherapy era

Chair: H. Tamura
Speaker: G. Morgan

17:00

Poster Viewing

Chair: J. Kuroda

Speaker: N. Sekiguchi

Chair: C. Shimazaki

Speakers: K. Mihara, S. Ito

18:00

Poster Session
18:00 - 19:00

19:00

Welcome Party
19:00 - 20:30（5F foyer）

23

ScheduleDay 3 : June 2 (Sun.), 2024

Room 1Room 2

Room 3

Poster Room501（5F）

502・503（5F）

411・412（4F）

409・410（4F）

8:00

Morning Seminar 1

8:10 - 8:50

Morning Seminar 2

8:10 - 8:50

Morning Seminar 3

8:10 - 8:50

Pitfalls of Mprotein Detection byImmunoﬁxation in plasma cell dyscrasias.

The Importance of Minimal Residual Disease (MRD) Analysis in
Myeloma Treatment in the Immunotherapy Era- Focusing on the characteristics and usefulness of Multicolor 10 -The importance of achieving well-being for
multiple myeloma patients andthe signiﬁcance of maintenance therapy【SEBIA JAPAN K.K. 】【LSI Medience Corporation】【Takeda Pharmaceutical CO., LTD.】

Chair: M. Kurokawa Speaker: Y. Kawano

Chair: M. Iino

Speaker: Y. Imai

Chair: K. Ohta Speakers: R. Ogawa, T. Ikeda

9:00

Symposium 5
9:00 - 10:30

Symposium 69:00 - 10:50

Therapeutic management of bone lesions
10:00

11:00

Multidisciplinary collaboration andteam medical care

Chairs:T. Harada, Y. Horigome

Chairs:N. Nishimura, I. Cye

Speakers:
T. Harada, H. Matsuzaki, M. Takasu, A. Kido

Speakers:
N. Yokota, M. Komuro, T. Eto, N. Ishibashi, K. Ohta

Oral Session2
10:40 - 11:50

Oral Session3
11:00 - 11:50

Basic and clinical research 2

Chairs:Y. Terui, R. Ogawa

Luncheon Seminar 4 12:00 - 12:50

New options for treatment of relapsed orrefractory multiple myeloma (RRMM)
Chair: H. Handa
Speaker: K. Sunami【Pﬁzer Japan Inc.】
13:00

Corporate Seminar 3

9:00 - 14:00

Multidisciplinary collaboration

Chairs:H. Handa, Y. Imai

12:00

Poster Viewing

13:00 - 13:50

BCMA-targeted therapies: an update
Chair: S. Iida
Speaker: M. Mohty【Pﬁzer Japan Inc. Medical Aﬀairs】

Luncheon Seminar 5 12:00 - 12:50

Secondary hypogammaglobulinemiaand infection
prevention in patients with multiple myeloma-The signiﬁcance of immunoglobulin replacement therapyChair: Y. Isobe Speaker: Y. Kuroda

Luncheon Seminar 612:00 - 12:50

Signiﬁcance of monitoring serum freelight chain in myeloma kidney andMGRS-associated renal lesions
Chair: H. Shibayama Speaker: S. Mizuno【CSL Behring K.K.】【Thermo Fisher Diagnostics K.K.】

Corporate Seminar 4 13:00 - 13:50

Educational Seminar 13:00 - 13:40

Appropriate patients and timing of patientreferral for BCMA CAR T therapy
Chair: T. Miyamoto
Speakers: M. Ri, S. Yoshihara

Chairs:Y. Kuroda, S. FuchidaSpeakers:
S. Ito, E. Sakaida【Bristol-Myers Squibb K.K.Japan Medical】

14:00

Patient and Public Involvement Program

Oral Session4
14:00 - 15:30

14:00 - 15:30

Promoting shared decision making forpatients to live well with myeloma

Treatment

15:00

16:00

Chairs:H. Shibayama, K. Sunami

Hosts:Y. Takamatsu, S. Shibata

Speakers:
Y. Takamatsu, S. Shibata, Y. Houri, N. Matsuura, A. Ikeda

PosterWithdrawal
14:00 - 17:00

Plenary Session
15:40 - 16:40
Chairs:M. Abe, C. Nakaseko

Speakers:
Y. Hattori, H. Ohguchi, K. Hachiya, A. Uehara, Y. Horigome

Closing Remarks
17:00

18:00

19:00

25